INFORMS's video: 2021 IAAA Winner Dynamic Ideas LLC Janssen Pharmaceuticals and MIT

Data-driven COVID-19 Vaccine Development for Janssen The COVID-19 pandemic has spurred extensive research in vaccine development. However, Phase III vaccine trials’ success highly depends on future COVID-19 incidence rates at trial sites. To accurately predict these rates, we created DELPHI, a novel policy-driven and machine-learning powered epidemiological model. DELPHI has been the centerpiece of site selection for Ad26.COV2-S, the leading vaccine candidate from Janssen. Team: Dimitris Bertsimas, Massachusetts Institute of Technology Michael Lingzhi Li, Massachusetts Institute of Technology Omar Skali Lami, Massachusetts Institute of Technology Hamza Tazi Bouardi, Massachusetts Institute of Technology Ali Haddad-Sisakht, Dynamic Ideas LLC Jennings Xu, Janssen Pharmaceuticals Jose Zamalloa, Janssen Pharmaceuticals Amir Hashemi, Janssen Pharmaceuticals Ankit Lodha, Janssen Pharmaceuticals Yuqi Shang, Janssen Pharmaceuticals Kris Standish, Janssen Pharmaceuticals Shi-hua Yu, Janssen Pharmaceuticals Levon Demirdjian, Janssen Pharmaceuticals Xiaoying Wu, Janssen Pharmaceuticals Sid Jain, Janssen Pharmaceuticals Najat Khan, Janssen Pharmaceuticals